NEUP (Neuphoria Therapeutics) Total Stockholders Equity : $13.75 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Total Stockholders Equity?

Neuphoria Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $13.75 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Neuphoria Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $8.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Neuphoria Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.01.

Neuphoria Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Neuphoria Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Total Stockholders Equity Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

8.71

35.76

39.15

22.01

17.49

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															-	19.78	17.49	17.07	13.75

Neuphoria Therapeutics (NAS:NEUP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Neuphoria Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(13.748	-	0)	/	1.629
	=	8.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Neuphoria Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.15	+	0.05)	/	13.748
	=	0.01

Neuphoria Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.